Europe eClinical Solutions Industry Size

The report "Europe eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, RTSM, eTMF, RIMS, eConsent), Application (Collection, Operation, Analytics), Trial Phase, End User (Pharma, Biotech, Medtech), Opportunities, Trends, Market Share - Forecast to 2030" is projected to grow from USD 3.18 billion in 2025 and to reach USD 5.86 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.0% during the forecast period.

Browse 178 market data Tables and 57 Figures spread through 238 Pages and in-depth TOC on "Europe eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, RTSM, eTMF, RIMS, eConsent), Application (Collection, Operation, Analytics), Trial Phase, End User (Pharma, Biotech, Medtech), Opportunities, Trends, Market Share - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-eclinical-solutions-market-111282618.html

Growth is supported by the expansion of large Phase III pipelines in oncology, CNS, and rare diseases, which is pushing sponsors to adopt integrated digital tools for faster study execution. The region is also witnessing a strong uptake of real-world data and digital endpoint validation to support the evidence generation demanded by European regulators and HTA bodies. Rising collaborations between academic medical centers and industry-led research networks are accelerating the adoption of modern eClinical platforms. The growing emphasis on site enablement and digital readiness, especially in Central and Eastern Europe, is driving investments in centralized monitoring, eCOA, and virtual visit tools.

The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the Europe eClinical solutions market, by end user, in 2024.

By end user, pharmaceutical and biopharmaceutical companies held the largest share of the market in 2024. Demand is increasing as European pharmaceutical companies move toward platform trials and master protocols, which require more flexible and scalable eClinical systems. Companies are also expanding the use of site-less and patient-centric trial models, especially for chronic and rare disease studies, driving the adoption of digital patient-engagement tools. The growing need to harmonize data across legacy systems, particularly following mergers and cross-border R&D consolidations, is pushing companies toward unified eClinical ecosystems. The rising dependence on predictive analytics for protocol optimization and enrollment forecasting is also boosting the usage of advanced digital platforms. In addition, the focus of the pharma sector on accelerating feasibility and study start-up processes in competitive therapeutic areas is increasing investment in automated workflow and document management tools.

The Phase IV trial phase is expected to show the fastest growth in the Europe eClinical solutions market, by clinical trial phase, during the forecast period.

By clinical trial phase, Phase IV is expected to grow at the fastest rate during the forecast period. Growth is rising because European regulators and payers demand real-world performance data to support reimbursement decisions, and are pushing sponsors to adopt digital tools for long-term evidence generation. The expansion of post-marketing safety commitments, especially for specialty and biologic therapies, is increasing the need for unified safety reporting and monitoring platforms. Companies are also leveraging EHR integration and national health registries across Europe, which drives the adoption of eClinical systems that can handle large, real-world datasets. The growth of decentralized follow-up models for chronic disease therapies is encouraging the use of remote data capture and ePRO solutions. Additionally, rising focus on subpopulation analysis to understand treatment differences across EU countries is boosting demand for advanced analytics within Phase IV programs.

Germany is expected to have a significant CAGR during the forecast period in the Europe eClinical solutions market due to the growing decentralization of clinical trials and increased use of remote data capture models across therapeutic areas. And sponsors are also responding to heightened regulatory scrutiny by investing in real-time monitoring, audit-ready systems, and advanced analytics to reduce trial risk and delays. Additionally, the rising collaboration between academic research centers, CROs, and digital health vendors is accelerating the adoption of flexible eClinical platforms that support hybrid and multisite study designs.

Key Players

The report profiles key players such as Medidata (A Dassault Systèmes Company) (France), Veeva Systems (US), IQVIA (US), ICON plc (Ireland), Signant Health (US), Clario (US), Oracle (US), and Clinion (US), among others.

Don’t miss out on business opportunities in Europe eClinical Solutions Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/